ArticleStatistics in medicine2021
Estimation and modeling of the restricted mean time lost in the presence of competing risks.
Article in Statistics in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Neoadjuvant and adjuvant treatment for pancreatic ductal adenocarcinoma in patients over 80 years old based on a nationwide clinical database.Journal of gastroenterology · 2026Article
- Balancing Days at Home and Major Adverse Limb Events After Surgical Versus Endovascular Lower-Extremity Revascularization in Chronic Kidney Disease.Journal of the American Heart Association · 2026Article
- Temporal trends in associations between social drivers and life-years lost in newly diagnosed atrial fibrillation in Denmark, 2000-22: a nationwide cohort study.The Lancet. Public health · 2026Article
- Early use of albumin may increase the risk of sepsis-associated acute kidney injury in sepsis patients: a target trial emulation.Military Medical Research · 2025Article
- Multi-group global tests for restricted mean survival time and restricted mean time lost: a variable transformation approach.BMC medical research methodology · 2025Article
- Addition of Macrolide Antibiotics for Hospital Treatment of Community-Acquired Pneumonia.The Journal of infectious diseases · 2025Article
- Longer disease progression milestone-free time in people with amyotrophic lateral sclerosis treated versus not treated with intravenous edaravone: results from an administrative claims analysis.Journal of comparative effectiveness research · 2025Observational
- Emulating the EPIC trial using VetCompass primary-care data: causal effects of pimobendan in UK dogs with grade IV/VI heart murmurs.PloS one · 2025Article
- Using Restricted Mean Time Lost to Evaluate the Prognostic Effects on Locally Advanced Breast Cancer Considering Competing Risks.Clinical epidemiology · 2025Article
- Modeling Recovery Housing Retention and Program Outcomes by Justice Involvement among Residents in Virginia, USA: An Observational Study.International journal of offender therapy and comparative criminology · 2024Observational
- Assessing treatment effects with adjusted restricted mean time lost in observational competing risks data.BMC medical research methodology · 2024Article
- Temporal trends in lifetime risks of atrial fibrillation and its complications between 2000 and 2022: Danish, nationwide, population based cohort study.BMJ (Clinical research ed.) · 2024Article
- Time-varying effect in older patients with early-stage breast cancer: a model considering the competing risks based on a time scale.Frontiers in oncology · 2024Article
- Studentized permutation method for comparing two restricted mean survival times with small sample from randomized trials.Statistics in medicine · 2023Article
- Article
- Power and Sample Size Calculations for the Restricted Mean Time Analysis of Prioritized Composite Endpoints.Statistics in biopharmaceutical research · 2023Article
- Counterfactual mediation analysis in the multistate model framework for surrogate and clinical time-to-event outcomes in randomized controlled trials.Pharmaceutical statistics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Survival data with competing or semi-competing risks are common in observational studies. As an alternative to cause-specific and subdistribution hazard ratios, the between-group difference in cause-specific restricted mean times lost (RMTL) gives the mean difference in life expectancy lost to a specific cause of death or in disease-free time lost, in the case of a nonfatal outcome, over a prespecified period. To adjust for covariates, we introduce an inverse probability weighted estimator and its variance for the marginal difference in RMTL. We also introduce an inverse probability of censoring weighted regression model for the RMTL. In simulation studies, we examined the finite sample performance of the proposed methods under proportional and nonproportional subdistribution hazards scenarios. We illustrated both methods with competing risks data from the Framingham Heart Study. We estimated sex differences in atrial fibrillation (AF)-free times lost over 40 years. We also estimated sex differences in mean lifetime lost to cardiovascular disease (CVD) and non-CVD death over 10 years among individuals with AF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.